Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies
作者： Giulio Cavalli , Charles A. Dinarello
DOI: 10.1093/RHEUMATOLOGY/KEV269
关键词: Interleukin 、 Canakinumab 、 Immunology 、 Proinflammatory cytokine 、 Rheumatoid arthritis 、 Inflammation 、 Medicine 、 Rilonacept 、 Anakinra 、 Receptor antagonist
摘要: The inflammatory cytokines IL-1α and IL-1β orchestrate local systemic responses underlying a broad spectrum of diseases. Three agents for reducing IL-1 activities are currently available. Anakinra is recombinant form the naturally occurring receptor antagonist. binds to prevents activity IL-1β. soluble decoy rilonacept neutralizing mAb canakinumab block A directed against anti-human in clinical trials. availability therapies specifically targeting unveiled pathological role IL-1-mediated inflammation broadening list Conditions effectively treated with blocking range from classic rheumatic diseases, such as RA gout, autoinflammatory syndromes, JIA FMF. However, antagonism also effective highly prevalent namely cardiovascular diseases type 2 diabetes, conditions that frequently encountered co-morbidities patients Thereby, inhibition has potential lift burden disease conditions, but provide benefits beyond efficacy on osteoarticular manifestations.
ru.nl
core.ac.uk
oxfordjournals.org
oup.com
sci-hub.se 参考文章(150)
P Aukrust, SS Froland, NB Liabakk, F Muller, I Nordoy, C Haug, T Espevik, Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. ,vol. 84, pp. 2136- 2143 ,(1994) , 10.1182/BLOOD.V84.7.2136.2136
CA Dinarello, Biologic basis for interleukin-1 in disease Blood. ,vol. 87, pp. 2095- 2147 ,(1996) , 10.1182/BLOOD.V87.6.2095.BLOODJOURNAL8762095
F.L. van de Veerdonk, M.G. Netea, C.A. Dinarello, J.W.M. van der Meer, Anakinra for the inflammatory complications of chronic granulomatous disease Netherlands Journal of Medicine. ,vol. 69, pp. 95- 95 ,(2011)
Philippe Goupille, Xavier Chevalier, Bruno Giraudeau, Thierry Conrozier, Jocelyne Marliere, Philippe Kiefer, Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. The Journal of Rheumatology. ,vol. 32, pp. 1317- 1323 ,(2005)
J Wagstaff, L L Thomsen, E M Rankin, A C Ogilvie, G J van Mierlo, A J Erenberg, C E Hack, K Hoekman, IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer. Journal of Immunology. ,vol. 156, pp. 389- 394 ,(1996)
Greta Guarda, Marion Braun, Francesco Staehli, Aubry Tardivel, Chantal Mattmann, Irmgard Förster, Matthias Farlik, Thomas Decker, Renaud A. Du Pasquier, Pedro Romero, Jürg Tschopp, Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation Immunity. ,vol. 34, pp. 213- 223 ,(2011) , 10.1016/J.IMMUNI.2011.02.006
Maria Giulia Cangi, Riccardo Biavasco, Giulio Cavalli, Greta Grassini, Elena Dal-Cin, Corrado Campochiaro, Barbara Guglielmi, Alvise Berti, Vito Lampasona, Andreas von Deimling, Maria Grazia Sabbadini, Marina Ferrarini, Claudio Doglioni, Lorenzo Dagna, BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease Annals of the Rheumatic Diseases. ,vol. 74, pp. 1596- 1602 ,(2015) , 10.1136/ANNRHEUMDIS-2013-204924
Bénédicte Neven, Isabelle Marvillet, Celine Terrada, Alice Ferster, Nathalie Boddaert, Vincent Couloignier, Graziella Pinto, Anne Pagnier, Christine Bodemer, Bahram Bodaghi, Marc Tardieu, Anne Marie Prieur, Pierre Quartier, Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis & Rheumatism. ,vol. 62, pp. 258- 267 ,(2010) , 10.1002/ART.25057
Rainer J. Egli, Lorraine Southam, James M. Wilkins, Inken Lorenzen, Manuel Pombo-Suarez, Antonio Gonzalez, Andrew Carr, Kay Chapman, John Loughlin, Functional Analysis of the Osteoarthritis Susceptibility―Associated GDF5 Regulatory Polymorphism Arthritis & Rheumatism. ,vol. 60, pp. 2055- 2064 ,(2009) , 10.1002/ART.24616
Peter Duewell, Hajime Kono, Katey J. Rayner, Cherilyn M. Sirois, Gregory Vladimer, Franz G. Bauernfeind, George S. Abela, Luigi Franchi, Gabriel Nuñez, Max Schnurr, Terje Espevik, Egil Lien, Katherine A. Fitzgerald, Kenneth L. Rock, Kathryn J. Moore, Samuel D. Wright, Veit Hornung, Eicke Latz, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals Nature. ,vol. 464, pp. 1357- 1361 ,(2010) , 10.1038/NATURE08938